| Note |
A new horizon in the treatment of depression. Moclobemide. Aurorix. Elevated efficacy. As effective as the tricyclics. Rapid commencement of action. Betters psychomotor activity. In patients active and of old age. Excellent tolerance. Better tolerance than the tricyclic anti-depressants. Without sedation that interferes with daily activities. Low risk of overdosage. Without enhancement of alcohol. Without anticholinergic effects. Without cardiotoxicity. Without provoking weight gain. Without adjustments in renal insufficiency. |